Department of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, Winnipeg, Man, Canada.
Department of Pediatrics, Section of Pediatric Pulmonary and Sleep Medicine, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colo.
J Allergy Clin Immunol Pract. 2022 Feb;10(2):453-459. doi: 10.1016/j.jaip.2021.11.020. Epub 2021 Nov 27.
The focus of this article is to review school asthma care during coronavirus disease 2019 (COVID-19). Asthma is listed as a risk factor in some guidelines, although children with asthma appear to not be at increased risk of severe respiratory outcomes compared with children without asthma during the pandemic. Differentiating COVID-19 from allergic disease is very difficult in the school-aged children. For school management, there is firm evidence that masks do not exacerbate underlying lung conditions including asthma, and evidence to date supports that children with asthma can learn in-person at school because they do not appear to be at increased risk of COVID-19 morbidity or mortality. For children and adolescents, the COVID-19 vaccine has been demonstrated to be safe and well tolerated. School asthma management includes remaining on prescribed asthma medications. Asthma management, as with management of all pediatric conditions, must also factor in the impact of adverse social determinants and health disparities. Broadly, the pandemic has also served as a call to resource stewardship and innovation and allowed practitioners to consider how this may impact asthma care moving forward.
本文的重点是回顾 2019 冠状病毒病（COVID-19）期间的学校哮喘护理。哮喘在一些指南中被列为危险因素，尽管与没有哮喘的儿童相比，哮喘儿童在大流行期间似乎没有更高的严重呼吸道后果风险。在学龄儿童中，区分 COVID-19 和过敏性疾病非常困难。对于学校管理，有确凿的证据表明口罩不会使包括哮喘在内的潜在肺部疾病恶化，并且迄今为止的证据支持哮喘儿童可以在学校面对面学习，因为他们似乎没有增加患 COVID-19 发病率或死亡率的风险。对于儿童和青少年，COVID-19 疫苗已被证明是安全且耐受良好的。学校哮喘管理包括继续使用处方哮喘药物。哮喘管理，就像所有儿科疾病的管理一样，还必须考虑到不利的社会决定因素和健康差异的影响。总的来说，大流行也促使人们对资源管理和创新进行思考，并让从业者考虑这将如何影响未来的哮喘护理。
